2/2/2007 Vancouver, British Columbia, Canada press release Genetic Engineering News (www.genengnews.com) LED Medical Diagnostics Inc., a Vancouver-based medical device company, recently closed a USD 6 million financing round through Integral Wealth Securities Limited. The company will use these funds to aggressively market and distribute its FDA (510k) cleared VELscope (Visually Enhanced Lesion Scope) oral mucosal examination device in the United States and Canadian dental markets through its wholly owned subsidiary, LED Dental Inc. VELscope is a clinically proven adjunctive screening device that utilizes a narrow band of blue light and specialized filtering technology to help dental professionals evaluate oral mucosa for abnormal areas of concern, such as potentially cancerous lesions that may not be apparent under white light. In addition, this round of funding will enable LED Medical to accelerate its efforts to integrate the use of VELscope into the oral hygiene and oral pathology curricula of leading dental schools throughout North America. According to Peter Whitehead, CEO and Director of LED Medical: "This oversubscribed round of financing was a resoundingly strong vote of confidence by the investment community for our proprietary Direct Tissue Fluorescence Visualization Technology and the potential it has to help save lives." VELscope was proven effective in clinical trials conducted by the British Columbia Cancer Agency (BCCA) and financed in part by over $50 million in grants from the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, a U.S. government-funded agency. "VELscope's improved real-time visual detection capability can significantly enhance [...]

2/2/2007 web-based article M Pabiszczak et al. Otolaryngol Pol, January 1, 2006; 60(5): 691-5 Assesment of recurrences in the oral cavity and pharynx is a serious diagnostic challenge particularly in patient after surgery and irradiation. Observed visible local lesions like oedema, formation of postoperative scars and pain made the diagnostic procedure difficult. Sometimes it's impossible to distinguish recurrences and inflammatory reaction. The aim of this research was to evaluate the usefulness of toluidyne blue in monitoring of recurrences and second primary tumors in the patients with oral and pharyngeal cancer. It was performed by comparison of the three methods: physical examination, endoscopic ultrasound probe and toluidine blue staining in detection of early malignancy. A group of 80 patients with oral and pharyngeal squamous cell cancer was treated in the years between 2000-2003 in the Department of Otolaryngology in Pozna?. In 7 positive tested cases toluidine blue staining was confirmed in histological examination. 3 cases were false-positive staining (patients after reconstructive with infrahyoid and pectoral major flap). Conclusions: (1) toluidine blue staining is a cheap effective diagnostic procedure for monitoring recurrences in patients after surgery and irradiation; (2) procedure is limited in patients after reconstructive flap surgery; (3) ultrasound endoscopy is of value in assesment of advanced tumors of oral cavity and pharynx, but it's limited in flat and superficial mucosal infiltrations. Authors: M Pabiszczak, M Wierzbicka, E Wasniewska, and W Szyfter Authors' affiliation: Klinika Otolaryngologii i Onkologii Laryngologicznej w Poznaniu im. K. Marcinkowskiego

2/2/2007 web-based article staff CancerConsultants.com A phase II multicenter trial has demonstrated that Ethyol (amifostine) can be administered subcutaneously for the prevention of radiation induced xerostomia in patients receiving radiation therapy for head and neck cancer. The details of this study appeared in the February 2007 issue of the International Journal of Radiation Oncology Biology Physics. Radiation therapy is commonly used to treat patients with head and neck cancers, and xerostomia is a frequent side effect. The intravenous administration of Ethyol has been approved by the U.S. Food and Drug Administration for prevention of radiation induced xerostomia. The necessity of administering Ethyol intravenously has severely limited its use. Thus, researchers have explored the subcutaneous route of administration. These researchers treated 54 patients with subcutaneous Ethyol followed by radiation therapy. The incidence of grade 2 or greater early Xerostomia was 56% and the incidence of late xerostomia was 45%. These incidences of early and late xerostomia are similar to that observed with the use of Ethyol intravenously in a previous randomized trial and lower than the control group of that trial. Nausea and vomiting were the most frequent side effects. Local control and survival rates were not inferior to those expected. These authors concluded that subcutaneous Ethyol could substitute for intravenous administration for the prevention of xerostomia. Comments: These are important observations that should increase the use of Ethyol in preventing xerostomia in patients with head and neck cancer. It is anticipated that the FDA will approve this route of administration. [...]

2/2/2007 New York, NY Megan Rauscher CancerPage.com In a retrospective case-control study, researchers observed a non-significant trend for better survival in head and neck cancer patients who used nonselective COX inhibitors (aspirin and/or nonsteroidal anti-inflammatory medications) on a regular basis. "Although these results are intriguing, there is not sufficient evidence to recommend their use in patients with head and neck cancer unlike patients with colon polyps or colon cancer," Dr. M. Boyd Gillespie from the Medical University of South Carolina warned in comments to Reuters Health. For the study, reported in the January issue of the Archives of Otolaryngology--Head and Neck Surgery, Dr. Gillespie and colleagues identified 325 head and neck squamous cell carcinoma patients. They compared the rate of COX inhibitor use among patients who had died or whose disease had recurred with that among survivors or those without recurrence. Medication data were available for 319 subjects, of whom 232 (73%) were COX inhibitor users and 87 (27%) were nonusers. There was no difference in COX inhibitor exposure between patients with and without disease recurrence (p = 0.42). "Although non-selective COX inhibitors are inexpensive, widely available, and relatively safe, they do not appear to have a strong effect at preventing recurrences of head and neck cancer," Dr. Gillespie said. There was also no significant difference in COX inhibitor use between survivors and nonsurvivors of head and neck cancer (p = 0.66). Nevertheless, there was a trend toward longer survival with regular COX inhibitor use. The median survival of COX [...]

1/31/2007 Vancouver, British Columbia, Canada press release NewsWire (www.newswire.ca) Perceptronix Medical Inc. today announced its participation in a research project to detect early oral cancer lesions through a new initiative inside the BC Oral Cancer Prevention Program. This Program is bringing together a network of dentists, researchers and technology companies to develop early screening programs for oral cancer. Participation in this program is a result of a collaborative research agreement signed between Perceptronix and researchers with the BC Cancer Agency. "The problem with oral cancer," says Dr. Miriam Rosin, Director of the BC Cancer Agency's Oral Cancer Prevention Program and lead investigator in the study, "is that there are often no symptoms in the early stages. And because it is a challenge to identify during the early stages, it is typically not diagnosed until the cancer has advanced and it is less responsive to treatment." The National Cancer Institute of Canada estimates there were 3,000 new oral cancer cases and 1,100 deaths from the disease in 2006. "During a routine dental exam, there are few clear signs to tell a dentist whether a sore in the mouth is due to inflammation, infection or cancer. The tools developed by Perceptronix and LED Dental Inc. could assist dentists in making those distinctions," added Dr. Rosin. Patients volunteering for the screening program will be checked for early cancer using the VELscope(R) fluorescence device developed by LED Dental Inc. The VELscope will aid in identifying areas that require further investigation. The next step involves [...]

1/26/2007 Gaithersberg, MD press release BusinessWire (home.businesswire.com) GenVec, Inc. today announced that the first patient has been dosed in a Phase I/II trial with TNFerade™ for head and neck cancer at the University of Chicago Medical Center. GenVec is sponsoring two separate Phase I/II studies at the University of Chicago to explore the use of TNFerade as a second-line treatment for unresectable, recurrent tumors, and as a first-line treatment for elderly or frail patients. The trials are being funded by the National Cancer Institute. The two separate trials, which will be led by principal investigators Everett Vokes, M.D., and Tanguy Seiwert, M.D., could enroll up to 70 patients with unresectable, recurrent tumors and up to 60 elderly or frail patients with new onset, locally advanced disease. The investigators will first determine best dose in each indication, and will assess safety and locoregional control of the cancer following TNFerade treatment as a component of standard of care. “The start of these trials marks another milestone in our clinical progress with TNFerade,” stated Mark Thornton, M.D., M.P.H., Ph.D., GenVec’s senior vice-president of product development. “We know that local control is crucial for effective treatment of head and neck cancers, and is a respected regulatory endpoint. Since TNFerade is administered directly at the tumor site, it is ideally suited for these specific indications. TNFerade also has a well-established safety profile, so we believe it is a potentially appropriate treatment for elderly or frail cancer patients who cannot tolerate the cytotoxic effects of systemically [...]

1/26/2007 Salt Lake City, UT press release PharmaLive (www.pharmalive.com) BSD Medical Corp. today announced that BSD was among 29 companies selected to exhibit at the 3-day Multidisciplinary Head and Neck Cancer Symposium, an international symposium dedicated to treatment of head and neck cancers, just concluded in Rancho Mirage, California. The symposium was jointly sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society of Clinical Oncology and the American Head and Neck Society, partnering together for the first time in this meeting. At the symposium, attended by approximately 400 physicians, worldwide experts presented the latest advances in the management of head and neck cancer, focusing on treatment options, innovative technology, clinical management issues and supportive outcomes. BSD Medical representatives used the symposium to emphasize a study conducted by Riccardo Valdagni, MD and Maurizio Amichelli, MD at the Oncology Center of Ospedale Santa Chiara, Trento, Italy, comparing the results for head and neck cancer patients who were treated with radiation alone to those who received hyperthermia therapy plus radiation. The patients involved had inoperable Stage IV head and neck cancer with metastatic lymph nodes. The study concluded that hyperthermia added to radiation improved complete response (tumor disappearance) from 41% to 83%, local relapse-free survival from 24% to 68% and overall survival at 5 years from 0% to 53%, as compared to radiation treatments alone. The study, published in the International Journal of Radiation Oncology, Biology, Physics (see Vol. 28, pp. 163-169), was halted on an ethical basis at [...]

1/24/2007 Pittsburgh, PA Marilyn Brooks WTAE.TV (www.thepittsburghchannel.com) Slowly but surely, scientists are unraveling the mysteries of cancer, and they said some of the discoveries are truly surprising. The new study focuses on head and neck tumors, but it could have even wider implications. Researchers in Cleveland said they've made a breakthrough discovery that could help future cancer diagnosis not just in head and neck tumors but all types of cancers. Scientists study all types of cancer by examining the tumor. They've done that for years. But they made the recent discovery while looking at the DNA in tissue surrounding the tumor. "This is, for the first time, we have looked at the stroma, or the innocent, surrounding cells in head and neck cancer and have found genetic alterations that are very similar to the cancer itself, so that's a first and it's stunning," said Dr. Charis Eng. Researchers analyzed DNA from 122 people with head and neck squamous cell carcinoma and found it similar to the DNA found in more common forms of skin cancer caused by sun exposure. Researchers believe this one is not sun-related but rather caused by smoking or other kinds of tobacco use. Head and neck cancers are difficult to treat, because it has already grown by the time the diagnosis is made. The American Cancer Society reports half of those diagnosed won't survive the disease. Eng said she hopes her findings will one day improve survival rates. "We have now uncovered a new target for [...]

1/24/2007 Usurbil, Spain press release Basque Research (www.basqueresearch.com) A researcher of the University of Navarra Beatriz Honorato has developed a panel of markers which distinguish those patients with squamous cell cancer of the head and neck who have the best survival rates. Her doctoral dissertation, defended at the School of Sciences and developed in the Biotechnology Laboratory of the University Hospital, may help to optimize chemotherapy and X-ray treatments, according to the current situation of each patient. For her dissertation, the scientist analyzed the response mechanisms to the therapies against tumorous tissues. In this way, knowing that the DNA repair systems are involved in the response to chemotherapy or X-ray therapy, Dr. Honorato has made advances in the study of the phenomena of resistance to these therapies in order to predict which patients will respond best. In speaking of resistance phenomena, we are referring to the absence of response to the treatment, which translates into the fact that the tumor either does not reduce in size, or else increases in size. Despite recent advances in the struggle against this disease, those patients with locally advanced cancers constitute a group with a poor prognosis, and this situation has not improved over the last ten years. With the objective of halting this tendency, her research has examined the involvement of these repair systems in the prognosis of all types of cancer patients. More than 4,000 new cases each year in Spain Head and neck cancer is one of the tumors with the [...]

1/24/2007 Boston, MA Dr. Deanna Lites WHDH (www.whdh.com) Every hour someone in this country dies of oral cancer. One of the reasons: it's often not detected until it's too late. But new technology approved by the FDA is hoping to change that. Dentist Steven Spitz is performing a cancer screening. An oral cancer screening is part of a routine dental exam where dentists look for abnormal tissue, but there are limitations with the naked eye. That's why some dentists, like Dr. Spitz, are turning to high tech equipment for help. It's called Velscope and can help dentists find oral cancer in its earliest stage. "The Velscope uses a natural fluorescence of light to excite the tissues and give a fluorescence of tissue back so that we can see the different colors," Dr. Steven Spitz, of Smileboston, said. Normal tissue looks pink to your eye. When you look at healthy tissue with the Velscope it will appear green and if it's abnormal it will be dark. "This black area, that's an area of concern telling us there's abnormal tissue," Dr. Spitz said. "We can see things that we never would have looked at or given a second thought of before." Dentists aren't the only ones happy with the quick and painless test. Joanne Finnegan's oral screening was A-okay. "I think it's great it was so simple and to be able to find that information before it becomes more advanced it's a great tool," Joanne said. Not all insurance companies cover the [...]